A real-world research of 2,843 adult patients having NAFLD with metabolic comorbidities from Russia revealed that PPC could consistently decrease AST, ALT, and GGT levels (p < 0.001), and another meta-analysis also showed that PPC was effective in lowering AST, ALT, and TBil levels (p < 0.01) (Maev et al., 2020; Luo et al., 2021). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.